EMERYVILLE, Calif., Feb. 14 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) today announced the date of its first annual Research & Development Day to be held on Tuesday, March 4, 2008. The event will take place from 8:00 to 9:30 a.m. at the Mandarin Oriental Hotel, 80 Columbus Circle, 36th Floor, South Salon, in New York City.
The focus of the meeting will be Viprinex(TM) (ancrod), NTI’s compound for the treatment of acute ischemic stroke, currently in two Phase 3 clinical trials.
Questions about the R&D Development Day can be directed to Walter Kass, NTI Investor Counsel, 212-300-4708.
About Neurobiological Technologies, Inc.
NTI is a biopharmaceutical company focused on developing novel agents for central nervous system conditions. The Company’s most advanced product candidate is Viprinex (ancrod), a novel multi-targeted agent currently undergoing pivotal Phase 3 clinical testing for the potential treatment of acute ischemic stroke.
CONTACT: Craig W. Carlson, VP & CFO of Neurobiological Technologies, Inc.,
+1-510-595-6000; or Walter Kass of Cordon Partners, LLC, +1-212-300-4708,
for Neurobiological Technologies, Inc.
Web site: http://www.ntii.com/
